Marché mondial des tests de diagnostic des immunoprotéines – Tendances et prévisions de l’industrie jusqu’en 2030

Analyse et taille du marché des tests de diagnostic des immunoprotéines

L'énorme prévalence des maladies chroniques augmente la demande de tests de diagnostic par immunoprotéines. Selon les données de l'OMS, l'Observatoire mondial de la santé estime qu'environ 1,6 million de personnes, soit 2,8 % du total des décès, sont dues au diabète. Les tests de chimioluminescence ont été rapidement développés grâce aux énormes avancées technologiques dans le domaine du diagnostic par immunoprotéines. Il existe plusieurs technologies qui aident à la détection rapide des maladies chroniques grâce à des outils entièrement automatisés.

Français Data Bridge Market Research analyse que le marché des tests de diagnostic d’immunoprotéines devrait atteindre 14,58 milliards USD d’ici 2030, soit 8,36 milliards USD en 2022, et devrait subir un TCAC de 7,2 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l’épidémiologie des patients, l’analyse du pipeline, l’analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des tests de diagnostic des immunoprotéines

Market Definition

Immunoproteins are the blood proteins which are involved in playing a major role in the functioning of the immune system. These proteins contain an immunological activity against pathogenic substances since they display an abnormal increase in blood concentration thus acting as a standard indicator in disease diagnosis during an unhealthy state. The immunoproteins form a whole body system in cells, tissues or organs which help to balance the dangerous effects of antigens.

Immunoprotein Diagnostic Testing Market Dynamics

Drivers

• Increasing Incidence of Chronic Diseases

The major reason for the growth in the demand for immunoprotein diagnostic testing services is the rise in incidence and incidence rate of chronic diseases. As per the records of WHO, the Global Health Observatory recommends that nearly 1.6 million, which is around 2.8% of the total deaths, are caused by diabetes. Furthermore, lung cancer alone was primarily responsible in 2012 to cause around 1.6 million deaths as per the statistics of WHO report. In this regard, early diagnosis and testing is necessary. This boosts the market growth.

• Rising Incidence of Non-communicable Diseases and Diabetes

As per the WHO records, the number of people having diabetes has increased from 108 million in 1980 to 422 million in 2014, indicating a huge rise in the incidence of diabetes. Furthermore, as per the Global Health Observatory data by WHO in 2017, about 70% of global deaths lead to 39.5 million are caused because of non- communicable diseases (NCD) such as cardiovascular diseases, cancers, chronic lung diseases, and diabetes. Thus, it leads to the increase in these testing patterns.

Opportunities

• Rise in Diagnostic Tests

There are several diagnostic tests that are helping in the expansion of the market growth. C-Reactive Protein (CRP) tests is widely used due to the wide product portfolio of major market players. These tests help to identify inflammation by determining the amount of CRP in the patient. It also help in observing the effectiveness of treatment for several infectious diseases and cancer. Furthermore, free light chain diagnostic tests are expected to show major growth during the forecast period. This is because of their ability to help in detection, diagnosis, and monitoring of plasma cell disorders. This testing is beneficial for patients suffering from light chain-only multiple myeloma, oligosecretory myeloma, or nonsecretory myeloma. Thus, all these tests are increasing the market growth.

• Growing Demand of Chemiluminescence assay

Chemiluminescence assay is projected to show the maximum growth during the forecast period because of its high specificity and sensitivity along with ability to identify antigens in human serum and plasma samples. Chemiluminescence assay is often characterized as a major tool for quick diagnosis of numerous diseases and is determined to be more accurate than fluorescence-based detection of labelled probes. Thus, this assay is certainly growing the market growth.

Restraints/Challenges

• High cost of Diagnostic Tests

Different tests are available for testing chronic diseases, cardiovascular and other conditions such as diabetes. But these tests are of much high cost which is not afforded by many patients, especially belonging to the lower economic groups. Thus, it hampers the market growth.

This immunoprotein diagnostic testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunoprotein diagnostic testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Bio-Rad partnered with Seegene, which is a major market player in multiplex molecular diagnostics, used for the clinical commercialization and huge development of infectious disease diagnostic solutions
• In 2021, Roche collaborated with PathAI, which is a world leader in pathology-based AI-powered technology. The companies collaborated intending to jointly develop an embedded image analysis workflow for different pathologists

Global Immunoprotein Diagnostic Testing Market Scope

The immunoprotein diagnostic testing market is segmented on the basis of type, applications, technology and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• C-Reactive Protein Diagnostic Test
• Complement System Protein Diagnostic Test
• Pre-Albumin Diagnostic Test
• Haptoglobin Diagnostic Test
• Immunoglobulin Diagnostic Test
• Free Light Chain Diagnostic Test
• Others

Applications

• Autoimmune Testing
• Infectious Disease Testing
• Allergy Testing
• Endocrine Testing
• Oncology Testing
• Toxicology Testing
• Others

Technology

• Radioimmunoassay
• Immunoturbidity Assay
• Immunoprotein Electrophoresis
• Enzyme-Linked Immunosorbent Assay
• Others

End-User

• Hospital and Clinics
• Diagnostic Laboratories
• Others

Immunoprotein Diagnostic Testing Regional Analysis/Insights

The immunoprotein diagnostic testing market is analyzed and market size insights and trends are provided by type, applications, technology and end-user as referenced above.

The countries covered in the immunoprotein diagnostic testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the immunoprotein diagnostic testing market because of the growing incidences of cancer with increasing number of diagnostic instruments and laboratories. Furthermore, high occurrence of cancer among the U.S. population also led to the huge growth of this market. Furthermore, high occurrence of cancer among the U.S. population also led to the growth of this market.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to high frequency of cancer and diabetes among the U.S.  population. Surge in number of government initiatives undertaken in Germany to conduct different tests for people who are suffering from multifactorial and chronic diseases, particularly to detect cancer, lung, diabetes, and cardiovascular disease, is one of the major factors which is responsible for the growth in this region.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.   

Croissance de la base installée des infrastructures de santé et pénétration des nouvelles technologies

Le marché des tests de diagnostic des immunoprotéines vous fournit également une analyse détaillée du marché pour chaque pays, la croissance des dépenses de santé pour les équipements en capital, la base installée de différents types de produits pour le marché des tests de diagnostic des immunoprotéines, l'impact de la technologie utilisant les courbes de vie et les changements dans les scénarios réglementaires des soins de santé et leur impact sur le marché des tests de diagnostic des immunoprotéines. Les données sont disponibles pour la période historique 2011-2020.

Analyse du paysage concurrentiel et des parts de marché mondiales des tests de diagnostic des immunoprotéines

Le paysage concurrentiel du marché des tests de diagnostic des immunoprotéines fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des tests de diagnostic des immunoprotéines.

Certains des principaux acteurs opérant sur le marché des tests de diagnostic des immunoprotéines sont :

• Abbott (États-Unis)
• Abcam plc (Royaume-Uni)
• Bio-Rad Laboratories, Inc. (États-Unis)
• Danaher. (États-Unis)
• DiaSorin SpA (Italie)
• Enzo Biochem (États-Unis)
• Diagnostic clinique orthopédique (États-Unis)
• Thermo Fisher Scientific Inc. (États-Unis)
• bioMérieux SA (France)
• Agilent Technologies Inc. (États-Unis)
• Enzo Life Sciences, Inc (Inde)
• Randox Laboratories Ltd (Royaume-Uni)
• SERVA Electrophoresis GmbH (Allemagne)
• Calbiotech (États-Unis)
• Eurobio scientifique (France)
• Meridian Bioscience, Inc. (États-Unis)
• A. Menarini Diagnostics srl (Italie)
• Lilly (États-Unis)
• F. Hoffmann-La Roche SA (Suisse)
• Mylan NV (États-Unis)
• Siemens Healthcare GmbH (Allemagne)

SKU-56900